This Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study.~This is a 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study.~7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.